Topical Tranexamic Acid and Acute Blood Loss in Total Hip Arthroplasty

Osteoarthritis, Hip Clinical Trial

Official title:

Topical Tranexamic Acid and Acute Blood Loss in Total Hip Arthroplasty

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01683955
• Other study ID #: TEAHIPS
• Status: Completed
• Phase: Phase 1
• Start date: January 1, 2013
• Est. completion date: November 3, 2013

Study information

• Verified date: March 2023
• Source: Henry Ford Health System
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to assess postoperative blood loss and transfusion rates in total hip replacement after one-time administration of topical tranexamic acid.

Description:

Autologous (donor) blood transfusion is an expensive and common occurrence after total hip replacement. There have been many proposed adjunctive measures to decrease intraoperative and postoperative blood loss during such surgery. Most of these include thrombin inhibition, so-called "minimally- invasive" techniques or instrumentation, or other adjunctive drugs. Hitherto, tranexamic acid, a specific drug that promotes part of the clotting cascade, has been used extensively in multiple areas of surgery with multiple studies evaluating its efficacy in cardiac surgery, spinal procedures, and as a dental swishing solution after tooth extraction. There have been small studies evaluating intravenous tranexamic acid and its effect on total hip replacements, with some promising results. The topical form of TA has been evaluated in only one prospective, randomized clinical trial with a significant decrease in postoperative blood loss and a trend towards decreased autologous blood transfusion rates. This study proposes to further evaluate tranexamic acid as an inexpensive and viable option for use in total hip arthroplasty. The topical form of the drug has been shown to achieve these hemostatic effects without increasing the risk of blood clots after surgery. A rigorous analysis of the effects of tranexamic acid demand a more standardized approach. Such a regimen is practiced at Henry Ford Hospital as all patients on the Adult Reconstruction service are placed on an identical dose of enoxaparin (a subcutaneous blood thinner) postoperatively for two weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 139
• Est. completion date: November 3, 2013
• Est. primary completion date: November 3, 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• All adult patients over age eighteen

• Primary unilateral total hip arthroplasty at Henry Ford Hospital (Detroit, Michigan, United States) and Henry Ford West Bloomfield Hospital (West Bloomfield, Michigan, United States)

Exclusion Criteria:

• patient history of venous thromboembolic disease or coagulopathy

• use of anticoagulant medications within 7 days of surgery

• history of arterial embolic disease

• history of Class III or IV heart failure

• renal failure

• intraoperative cardiovascular, pulmonary, orthopaedic, or anesthetic complication (MI, intraoperative fracture, vasopressor support, emergent intubation).

Related Conditions & MeSH terms

• Acute Blood Loss Anemia
• Hemorrhage
• Osteoarthritis, Hip

Intervention

Drug:
• Tranexamic acid
Topical tranexamic acid (2g/100mL 0.9% saline)
• Placebo
100mL 0.9% sterile saline

Locations

Country	Name	City	State
United States	Henry Ford Hospital	Detroit	Michigan
United States	HFH Main campus	Detroit	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
Henry Ford Health System

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	postoperative blood loss	Preoperative and lowest postoperative hemoglobin	participants will be followed for the duration of hospital stay, an expected average of 3 days
Secondary	postoperative transfusion rate	number of units transfused postoperatively	participants will be followed for the duration of hospital stay, an expected average of 3 days